Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ null H2-Ab1 tm1Gru Tg (human leucocyte antigen D-related 4) mice: A mouse model of human allogeneic graft-versus-host disease

Clinical and Experimental Immunology

Volumn 166, Issue 2, 2011, Pages 269-280

  Covassin, L ^a   Laning, J ^a   Abdi, R ^b   Langevin, D L ^a   Phillips, N E ^a   Shultz, L D ^c   Brehm, M A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

Graft versus host disease; IL 2R 'common' gamma chain; SCID; T cell

Indexed keywords

HLA DR4 ANTIGEN; INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BARE LYMPHOCYTE SYNDROME; BLOOD; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DIABETES MELLITUS; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; NONOBESE DIABETIC MOUSE; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; WEIGHT REDUCTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENES, MHC CLASS II; GRAFT VS HOST DISEASE; HLA-DR4 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, INTERLEUKIN-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 80053654946     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04462.x     Document Type: Article

References (57)

1. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol 2010; 125:S324-35.
2. Jenq RR, van den Brink MRM. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10:213-21.
3. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147:614-33.
4. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-61.
5. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7:340-52.
6. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25:139-70.
7. Duran-Struuck R, Reddy P. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2008; 85:303-8.
8. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98:3192-204.
9. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43:3-10.
10. Penack O, Holler E, van den Brink MR. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010; 115:1865-72.
11. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90:3204-13.
12. Hill GR, Teshima T, Gerbitz A etal. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104:459-67.
13. Cooke KR, Gerbitz A, Crawford JM etal. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107:1581-9.
14. Li M, Sun K, Welniak LA, Murphy WJ. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Exp Opin Pharmacother 2008; 9:2305-16.
15. Socié G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009; 114:4327-36.
16. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7:118-30.
17. Hesselton RM, Koup RA, Cromwell MA, Graham BS, Johns M, Sullivan JL. Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J Infect Dis 1993; 168:630-40.
18. Hoffmann-Fezer G, Gall C, Zengerle U, Kranz B, Thierfelder S. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 1993; 81:3440-8.
19. Martino G, Anastasi J, Feng J etal. The fate of human peripheral blood lymphocytes after transplantation into SCID mice. Eur J Immunol 1993; 23:1023-8.
20. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335:256-9.
21. Murphy WJ, Bennett M, Anver MR, Baseler M, Longo DL. Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions. Eur J Immunol 1992; 22:1421-7.
22. Tary-Lehmann M, Lehmann PV, Schols D, Roncarolo MG, Saxon A. Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras. J Exp Med 1994; 180:1817-27.
23. Tary-Lehmann M, Saxon A, Lehmann PV. The human immune system in hu-PBL-SCID mice. Immunol Today 1995; 16:529-33.
24. Cao T, Leroux-Roels G. Antigen-specific T cell responses in human peripheral blood leucocyte (hu-PBL)-mouse chimera conditioned with radiation and an antibody directed against the mouse IL-2 receptor beta-chain. Clin Exp Immunol 2000; 122:117-23.
25. Hippen KL, Harker-Murray P, Porter SB etal. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008; 112:2847-57.
26. Murphy WJ, Conlon KC, Sayers TJ etal. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J Immunol 1993; 150:3634-42.
27. Nervi B, Rettig MP, Ritchey JK etal. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol 2007; 35:1823-38.
28. Sandhu J, Shpitz B, Gallinger S, Hozumi N. Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J Immunol 1994; 152:3806-13.
29. Sandhu JS, Gorczynski R, Shpitz B, Gallinger S, Nguyen HP, Hozumi N. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation 1995; 60:179-84.
30. Shpitz B, Chambers CA, Singhal AB etal. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J Immunol Methods 1994; 169:1-15.
31. van Rijn RS, Simonetti ER, Hagenbeek A etal. Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality. Exp Hematol 2007; 35:117-27.
32. van Rijn RS, Simonetti ER, Hagenbeek A etal. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 2003; 102:2522-31.
33. Tournoy KG, Depraetere S, Meuleman P, Leroux-Roels G, Pauwels RA. Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice. Eur J Immunol 1998; 28:3221-30.
34. Tournoy KG, Depraetere S, Pauwels RA, Leroux-Roels GG. Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice. Clin Exp Immunol 2000; 119:231-9.
35. Shultz LD, Lyons BL, Burzenski LM etal. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174:6477-89.
36. King MA, Covassin L, Brehm MA etal. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 2009; 157:104-18.
37. King M, Pearson T, Shultz LD etal. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008; 126:303-14.
38. Ito R, Katano I, Kawai K etal. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 2009; 87:1654-8.
39. King M, Pearson T, Rossini AA, Shultz LD, Greiner DL. Humanized mice for the study of type 1 diabetes and beta cell function. Ann NY Acad Sci 2008; 1150:46-53.
40. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480-90.
41. Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI. Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 2009; 183:696-705.
42. Golovina TN, Mikheeva T, Suhoski MM etal. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008; 181:2855-68.
43. Wilson J, Cullup H, Lourie R etal. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 2009; 206:387-98.
44. McCluskey J, Kanaan C, Diviney M. Nomenclature and serology of HLA class I and class II alleles. In: Coligan JE, Kruisbeek AM, Margulies DM, Shevach EM, Strober W, eds. Current protocols in immunology. New Jersey: John Wiley & Sons, 2002:Appendix 1:S.1-S.8.
45. Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, Zaller DM. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J Exp Med 1994; 180:173-81.
46. Bunce M. PCR-sequence-specific primer typing of HLA class I and class II alleles. Methods Mol Biol 2003; 210:143-71.
47. Brehm MA, Mangada J, Markees TG etal. Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice. Blood 2007; 109:819-26.
48. Pino S, Brehm MA, Covassin-Barberis L etal. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol Biol 2010; 602:105-17.
49. Racki WJ, Covassin L, Brehm M etal. NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection. Transplantation 2010; 89:527-36.
50. Colf LA, Bankovich AJ, Hanick NA etal. How a single T cell receptor recognizes both self and foreign MHC. Cell 2007; 129:135-46.
51. Huseby ES, White J, Crawford F etal. How the T cell repertoire becomes peptide and MHC specific. Cell 2005; 122:247-60.
52. Felix NJ, Donermeyer DL, Horvath S etal. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8:388-97.
53. Jarchum I, Baker JC, Yamada T etal. In vivo cytotoxicity of insulin-specific CD8+ T-cells in HLA-A*0201 transgenic NOD mice. Diabetes 2007; 56:2551-60.
54. Takaki T, Marron MP, Mathews CE etal. HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes. J Immunol 2006; 176:3257-65.
55. Unger WW, Pinkse GG, Mulder-van der Kracht S etal. Human clonal CD8 autoreactivity to an IGRP islet epitope shared between mice and men. Ann NY Acad Sci 2007; 1103:192-5.
56. Ito K, Bian HJ, Molina M etal. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996; 183:2635-44.
57. Madsen L, Labrecque N, Engberg J etal. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci USA 1999; 96:10338-43.